Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an ...
"If the number of EVs increases, who will handle the work surrounding charging?"The materials outline movements where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results